NEW YORK, June 23, 2015 /PRNewswire/ --

This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by over 270 tables & figures over 254 pages. The personalized medicine (global) market is presented as follows:

By Company (e.g., 23andMe, AFFYMETRIX, ATOSSA GENETICS, NODALITY, deCode /Amgen, CELERA, MYRIAD) By Geography (US, UK, EU) By Segment (Targeted therapeutics, Companion Diagnostics, Esoteric tests, Esoteric lab services) By Sub-market (Companion diagnostics & therapeutic, nutrition & wellness, medical technology, pharmacogenomics, consumer genomics)

A wealth of financial data & business strategy information is provided including:

Company financials, sales & revenue figures Business Model Strategies for Diagnostic, Pharmaceutical and Biotechnology Companies Business Model Strategies for Providers. Provider Systems and Academic Medical Centres Business Model Strategies for Payers & Governments Private and Public Funding and Personalized Medicine Reimbursement Revisions to Current Payment Systems and intellectual property How to Gain Market Penetration in the EU Cost-effectiveness and Business Value of Personalized Medicine Consumer genomics and POC market Therapeutics and Companion Diagnostics (e.g., BRAC Analysis, Oncotype Dx , KRAS Mutations) Comprehensive account of company product portfolios & kits

SWOT, Economic & Regulatory Environment specifics include:

Key strengths, weaknesses and threats influencing leading player position within the market Technologies driving the market (e.g., New-Generation Sequencing Technologies, Ultra-High Throughput Sequencing) Top fastest growing market segments and emerging opportunities Top pharmaceutical companies within the IPM by market share and revenue Comprehensive product portfolios, R&D activity and pipeline therapeutics M&A activity and future strategies of top personalized medicine pharmacos Personalized Medicine Regulation (USA, UK, Germany, France, Spain, Italy) CE-marked Personalized Medicine/Diagnostic Tests FDA Advances in Personalized Medicine Regulation

This report highlights a number of significant pharmacos and gives details of their operations, products, financials and business strategy.

23andMe Affymetrix Astex Pharmaceuticals Atossa Genetics CuraGen Celera Corporation (Quest Diagnostics) Celldex Therapeutics deCode Genetics (Amgen) Illumina Genelex Myriad Nodality Qiagen What you will gain:

An in-depth understanding of the global personalized medicine market and it's environment Current market facts, figures and product lines of key players in the industry Emerging trends in key markets such as the US, UK, Germany and France Knowledge of how the personalized medicine market will integrate into the global healthcare market Technical insights into new generation sequencing technologies and ultra-high throughput sequencing Updates on bioinformatics, high throughput systems, genetic analysis kits, companion diagnostics and future technologies FDA approved pharmacogenetic tests and recognized biomarkers Information on key government and regulatory policies Strategies on how to adapt and restructure current business models to this industry

Read more from the original source:
Personalized Medicine, Targeted Therapeutics and Companion ...

Comments are closed.